Abstract
Angiogenesis is believed to play a critical role in cancer; however, antiangiogenic therapy has not been demonstrated to improve the survival of patients who have lung cancer. In this article, the evidence that supports a role for angiogenesis in the pathogenesis of lung cancer, trials of antiangiogenic agents in lung cancer performed to date, and the lessons learned from these studies are discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 1121-1141 |
| Journal | Hematology/Oncology Clinics of North America |
| Volume | 18 |
| Issue number | 5 |
| Publication status | Published - 1 Mar 2005 |
